Aptose Biosciences (APTO) Shares Down 11.1%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) shares were down 11.1% during mid-day trading on Thursday . The company traded as low as $1.85 and last traded at $2.00. Approximately 2,855,119 shares traded hands during mid-day trading, an increase of 933% from the average daily volume of 276,509 shares. The stock had previously closed at $2.25.

A number of analysts have recently commented on APTO shares. Zacks Investment Research raised Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research note on Monday, May 13th. Royal Bank of Canada started coverage on Aptose Biosciences in a research note on Friday, March 1st. They set an “outperform” rating and a $6.00 price target on the stock. HC Wainwright set a $9.00 price target on Aptose Biosciences and gave the company a “buy” rating in a research note on Friday, March 22nd. Finally, Roth Capital reissued a “buy” rating on shares of Aptose Biosciences in a research note on Thursday, May 23rd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $5.75.

The company has a market cap of $87.97 million, a P/E ratio of -2.33 and a beta of 1.57. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.93 and a quick ratio of 5.93.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.03. As a group, equities research analysts anticipate that Aptose Biosciences Inc. will post -0.61 EPS for the current fiscal year.

In related news, CFO Gregory K. Chow acquired 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The shares were bought at an average cost of $1.75 per share, with a total value of $26,250.00. Following the completion of the purchase, the chief financial officer now directly owns 122,014 shares in the company, valued at $213,524.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Erich Platzer sold 20,000 shares of Aptose Biosciences stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total value of $43,800.00. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 35,000 shares of company stock worth $63,750. 7.34% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the stock. Noven Financial Group Inc. acquired a new position in shares of Aptose Biosciences in the fourth quarter worth approximately $27,000. Jane Street Group LLC acquired a new position in shares of Aptose Biosciences in the first quarter worth approximately $35,000. Geode Capital Management LLC acquired a new position in shares of Aptose Biosciences in the fourth quarter worth approximately $33,000. Boston Advisors LLC acquired a new position in shares of Aptose Biosciences in the first quarter worth approximately $36,000. Finally, Patriot Financial Group Insurance Agency LLC lifted its stake in shares of Aptose Biosciences by 11.4% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock worth $110,000 after acquiring an additional 5,890 shares during the period. 7.93% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Aptose Biosciences (APTO) Shares Down 11.1%” was first published by Rockland Register and is the sole property of of Rockland Register. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://rocklandregister.com/2019/05/30/aptose-biosciences-apto-shares-down-11-1.html.

Aptose Biosciences Company Profile (NASDAQ:APTO)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Article: Treasury Bonds

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.